This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

bioRxiv · Jul 8, 2025 · PreprintCancer Biology

Spatial multi-omics and deep learning reveal fingerprints of immunotherapy response and resistance in hepatocellular carcinoma

Zhenqin Wu, Joseph Boen, Sonali Jindal, Sreyashi Basu, Matthew F Bieniosek, Siyu He, Michael Brian LaPelusa, Aaron T. Mayer, Ahmed Omar Kaseb, James Zou, Padmanee Sharma, Alexandro E. Trevino

This study uses spatial multi-omics and deep learning to identify immunotherapy response and resistance signatures in hepatocellular carcinoma.

bioRxiv · Jun 11, 2025 · PreprintCancer Biology

Somatostatin Receptor 2 Overexpression in Hepatocellular Carcinoma: Implications for Cancer Biology and Theranostic Applications

Majid Momeny, Servando Hernandez Vargas, Solmaz AghaAmiri, Jack T. Adams, Tyler M. Bateman, Sukhen C. Ghosh, Belkacem Acidi, Vahid Khalaj, Ahmed Omar Kaseb, Hop S. Tran Cao, Ali Azhdarinia

This study investigates SSTR2 overexpression in HCC, finding it correlates with poor survival and oncogenic pathways, suggesting it as a therapeutic target and theranostic biomarker.

bioRxiv · Jan 29, 2025 · PreprintCancer Biology

SSTR2-targeted theranostics in hepatocellular carcinoma

Majid Momeny, Solmaz AghaAmiri, Servando Hernandez Vargas, Belkacem Acidi, Sukhen C. Ghosh, Tyler M. Bateman, Jack T. Adams, Vahid Khalaj, Ahmed Omar Kaseb, Hop S. Tran Cao, Ali Azhdarinia

This study evaluates SSTR2-targeted theranostics for hepatocellular carcinoma, showing SSTR2 expression and effective radioligand uptake and cytotoxicity in preclinical and clinical settings.

Cancers · Jan 7, 2025Peer-reviewedCancer Biology